In this week\u2019s newsletter- BI announced the approval of a therapy for the treatment of insulin dysregulation in horses and ponies in Great Britain. A few weeks ago, we noted the publication of a peer-reviewed controlled trial in equine regenerative medicine for an allogenic equine umbilical cord connective tissue matrix. Could this be a sign of renewed interest in Equine product offerings?\u00a0\u00a0\u00a0 As a horse woman for 30+ years l sure hope so.\u00a0\u00a0Equine has long struggled finding a business unit home \u2013 should they be part of companion\u00a0animal,\u00a0reside\u00a0with livestock or be a dedicated team of their own?\u00a0From an R and D perspective the relatively\u00a0low number\u00a0of horse owning households (The American Pet Products Association 2025 survey lists it as 2 million households) and lack of recent and reliable number of horses make it extremely difficult to create financially justifiable market\u00a0potential\u00a0assumptions.\u00a0\u00a0So\u00a0for a long time, the equine health market has been seen somewhat of the wild west- with little need for traditional FDA product approvals or investments in solutions.\u00a0\u00a0However there seems to be a bit of a shift, the American Horse Council\u2019s 2023 Economic Impact of the Horse Industry gave us some insights \u2013 6.6 million horses, segmenting them into sectors such as racing, recreation and competition and more recently the legitimizing of the regenerative medicine (PRP) and pain management modalities (Laser, Chiropractic, Massage) for\u00a0humans.\u00a0\u00a0While it will always be dwarfed to the broader markets of\u00a0cats and\u00a0dogs\u00a0and livestock,\u00a0equine\u00a0shouldn\u2019t\u00a0be overlooked.\u00a0Don\u2019t\u00a0let their numbers define the whole story.<\/p>\n
Dr. Christine Merle, Editor<\/em><\/p>","protected":false},"excerpt":{"rendered":" No boletim informativo desta semana, a BI anunciou a aprova\u00e7\u00e3o de uma terapia para o tratamento da desregula\u00e7\u00e3o da insulina em cavalos e p\u00f4neis na Gr\u00e3-Bretanha. Algumas semanas atr\u00e1s, mencionamos a publica\u00e7\u00e3o de um ensaio cl\u00ednico controlado, revisado por pares, na \u00e1rea de medicina regenerativa equina, para uma matriz de tecido conjuntivo alog\u00eanico do cord\u00e3o umbilical equino. Ser\u00e1 este um sinal de renovado interesse em produtos para equinos? Como amante de cavalos h\u00e1 mais de 30 anos, certamente espero que sim. O setor equino tem lutado h\u00e1 muito tempo para encontrar um nicho de mercado definido \u2013 deve fazer parte da \u00e1rea de animais de companhia, estar associado ao gado ou constituir uma equipe dedicada exclusivamente a ele? Do ponto de vista de pesquisa e desenvolvimento, o n\u00famero relativamente baixo de fam\u00edlias propriet\u00e1rias de cavalos (a pesquisa da American Pet Products Association de 2025 estima esse n\u00famero em 2 milh\u00f5es) e a falta de dados recentes e confi\u00e1veis sobre o n\u00famero de cavalos tornam extremamente dif\u00edcil criar proje\u00e7\u00f5es de mercado financeiramente justific\u00e1veis. Assim, por muito tempo, o mercado de sa\u00fade equina foi visto como uma esp\u00e9cie de faroeste, com pouca necessidade de aprova\u00e7\u00f5es tradicionais de produtos pela FDA ou investimentos em solu\u00e7\u00f5es. No entanto, parece haver uma pequena mudan\u00e7a. O relat\u00f3rio "Impacto Econ\u00f4mico da Ind\u00fastria Equina 2023" do American Horse Council nos deu algumas informa\u00e7\u00f5es importantes: 6,6 milh\u00f5es de cavalos, segmentados em setores como corridas, recrea\u00e7\u00e3o e competi\u00e7\u00e3o, e, mais recentemente, a legitima\u00e7\u00e3o da medicina regenerativa (PRP) e das modalidades de controle da dor (laser, quiropraxia, etc.).,<\/p>\n